No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
234 |
4. Check minimum number of eventsNone |
234 |
5. Include endpointsNone |
234 |
6. Filter based on genotype QC (FinnGen only) |
210 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Wilms' tumor, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of kidney, except renal pelvis, including Hilmo
- Malignant neoplasm of urinary organs, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 210 | 74 | 136 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | 63.56 | 59.49 | 65.77 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 220
- Matched controls
- 2200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C64.80
ICD-10 Finland
Wilms tumour
+∞
315.3
219
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
220.7
173
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
112.6
160.9
84
12
8312/3-C64.9
ICD-O-3
Renal cell carcinoma, NOS, of kidney, NOS
+∞
129.3
111
*
130
Kela drug reimbursment
Malignant tumour
+∞
122.7
106
*
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
103.5
91
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
1393.4
95.4
86
*
8310/3-C64.9
ICD-O-3
Clear cell adenocarcinoma, NOS, of kidney, NOS
+∞
48.8
45
*
180
Kela drug reimbursment
Interferon alfa
+∞
39.8
37
*
JN4BD
NOMESCO Finland
Extensive body CT
11.1
36.9
43
47
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.8
36.9
74
153
A03FA01
ATC
metoclopramide; systemic, rectal
6.9
36.0
69
136
8960/3-C64.9
ICD-O-3
Nephroblastoma, NOS, of kidney, NOS
+∞
33.2
31
*
JN4AD
NOMESCO Finland
Body CT examination
9.1
32.2
44
59
H02AB02
ATC
dexamethasone; systemic
68.9
31.1
35
6
197
Kela drug reimbursment
Sunitinib
+∞
31.0
29
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
28.8
27
*
L01XE04
ATC
[U] sunitinib
+∞
28.8
27
*
KAC00
NOMESCO Finland
Nephrectomy
320.0
28.4
28
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.7
25.7
40
62
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
280.6
25.2
25
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
24.9
24.3
34
16
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
23.3
22
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
22.3
21
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
22.3
21
*
N02AA05
ATC
oxycodone; systemic
4.4
21.8
70
209
A04AA01
ATC
ondansetron; systemic, rectal
19.5
21.2
32
19
A04AA02
ATC
granisetron; systemic, transdermal
+∞
20.1
19
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.8
18.9
82
300
7125
FHL
Nephrectomy (extrrafascial)
206.9
18.8
19
*
Z51.5
ICD-10 Finland
Palliative care
7.1
18.5
30
48
WX302
NOMESCO Finland
Thoracal epidural anesthesy
14.9
18.1
30
23
ZXE20
NOMESCO Finland
More than three and less than five hours
4.3
17.4
54
155
159
Kela drug reimbursment
Pazopanib
+∞
16.9
16
*
GD1AD
NOMESCO Finland
Thorax CT examination
6.4
16.8
30
53
WF049
NOMESCO Finland
Radiotherapy of metastasis
183.3
16.7
17
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
36.4
16.0
20
6
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
28.8
15.9
21
8
116
Kela drug reimbursment
Prostate cancer
+∞
15.8
15
*
WW500
NOMESCO Finland
Blood transfusion
13.2
15.6
27
23
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.8
15.1
38
92
KAD00
NOMESCO Finland
Partial nephrectomy
86.0
14.8
16
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
14.7
14
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
160.2
14.6
15
*
A41.9
ICD-10 Finland
Sepsis, unspecified
6.1
14.2
26
47
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
13.7
13
*
N18.8
ICD-10 Finland
Other chronic renal failure
10.4
13.4
26
28
R50.9
ICD-10 Finland
Fever, unspecified
3.4
13.3
58
208
B01AB10
ATC
tinzaparin; parenteral
4.7
13.2
33
79
TK800
NOMESCO Finland
Hemodialysis
15.3
13.1
21
15
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
+∞
12.6
12
*
158
Kela drug reimbursment
Everolimus
+∞
12.6
12
*
UKC02
NOMESCO Finland
Cystoscopy
3.3
12.0
53
191
N02AX02
ATC
tramadol; systemic, rectal
2.7
12.0
111
600
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.0
11.8
22
22
168
Kela drug reimbursment
Axitinib
+∞
11.6
11
*
L03AA04, ,
ATC
+∞
11.6
11
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
11.6
11
*
1890A
ICD-9 Finland
Malignant neoplasm of kidney and other and unspecified urinary organs, Kidney, except pelvis[NEOPL MAL RENIS PELVI EXCEPTO,NEPHROBLASTOMA]
+∞
11.6
11
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
11.6
11
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
45.8
11.0
13
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
12.1
10.8
19
17
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
63.1
10.7
12
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.1
10.5
52
199
322
Kela drug reimbursment
Sunitinib
+∞
10.5
10
*
Z85.5
ICD-10 Finland
Personal history of malignant neoplasm of urinary tract
+∞
10.5
10
*
L01XE11
ATC
[U] pazopanib
+∞
10.5
10
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
10.3
42
143
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
10.2
91
474
JN4CD
NOMESCO Finland
Very extensive body CT
17.8
10.0
15
9
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
5.1
10.0
22
47
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
10.3
10.0
19
20
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
9.7
60
260
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.6
9.6
34
105
TPX10
NOMESCO Finland
Implantation of vascular injection port
13.2
9.5
16
13
R31
ICD-10 Finland
Unspecified haematuria
3.3
9.5
39
133
WF002
NOMESCO Finland
Radical radiotherapy
104.3
9.5
10
*
1890X
ICD-9 Finland
Malignant neoplasm of kidney and other and unspecified urinary organs, Kidney, except pelvis[NEOPL MAL RENIS PELVI EXCEPTO,EI HIST VAHV]
+∞
9.4
9
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
9.4
9
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
9.4
9
*
C648, ,
ICD-10 Finland
+∞
9.4
9
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
9.4
9
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
9.4
9
*
1890B
ICD-9 Finland
Malignant neoplasm of kidney and other and unspecified urinary organs, Kidney, except pelvis[NEOPL MAL RENIS PELVI EXCEPTO,ADENOCARCINOMA]
+∞
9.4
9
*
U75
ICPC
Malignant neoplasm of kidney
+∞
9.4
9
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
12.2
9.2
16
14
A06AD11
ATC
lactulose; oral
2.8
9.2
55
233
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
38.4
9.1
11
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
38.4
9.1
11
*
ZXD05
NOMESCO Finland
Urgent procedure
2.5
9.1
79
403
V03AE01
ATC
polystyrene sulfonate; oral
13.5
8.5
14
11
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
13.5
8.5
14
11
A12AA04
ATC
calcium carbonate; oral
13.5
8.5
14
11
L03AA02
ATC
filgrastim; parenteral
93.5
8.5
9
*
ZX120
NOMESCO Finland
Intravenous
3.8
8.4
27
78
L01XE10
ATC
[U] everolimus
+∞
8.4
8
*
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
+∞
8.4
8
*
L03AB04
ATC
interferon alfa-2a; parenteral
+∞
8.4
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
8.4
8
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
8.4
8
*
L02BB03
ATC
bicalutamide; oral
+∞
8.4
8
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
8.4
8
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
8.4
8
*
8260/3-C64.9
ICD-O-3
Papillary adenocarcinoma, NOS, of kidney, NOS
+∞
8.4
8
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
8.4
8
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
8.4
8
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.7
8.3
20
46
XX3DW
NOMESCO Finland
Time consuming IT work
5.1
8.3
18
38
B02AA02
ATC
tranexamic acid; systemic
3.5
8.2
30
95
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.7
8.1
19
43
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
13.7
8.0
13
10
B01AB05
ATC
enoxaparin; parenteral
2.4
7.9
71
364
B03XA02
ATC
darbepoetin alfa; parenteral
12.5
7.7
13
11
Z49.1
ICD-10 Finland
Extracorporeal dialysis
12.5
7.7
13
11
WZC00
NOMESCO Finland
Treatment plan or consultation
2.4
7.6
70
363
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.3
7.5
20
50
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.7
7.5
25
74
L02AB02
ATC
medroxyprogesterone; systemic
82.8
7.5
8
*
L01XE17
ATC
[U] axitinib
+∞
7.3
7
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
+∞
7.3
7
*
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
7.3
7
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
7.3
7
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
7.3
7
*
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.7
7.2
24
71
N02AA01
ATC
morphine; systemic, rectal
12.6
7.2
12
10
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.7
6.9
23
68
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
11.5
6.9
12
11
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
6.9
89
527
TPH07
NOMESCO Finland
Cathetrisation of artery
2.9
6.9
36
141
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
17.4
6.8
10
6
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
17.4
6.8
10
6
A11CC03
ATC
alfacalcidol; systemic
6.8
6.8
16
25
WZC30
NOMESCO Finland
Teaching
2.9
6.8
35
136
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.3
6.8
17
29
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
6.7
111
720
M05BX04
ATC
denosumab; parenteral
4.1
6.7
19
50
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.4
6.7
25
80
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
12.8
6.7
11
9
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
6.5
54
265
ZX121
NOMESCO Finland
Central venous catheter
71.8
6.5
7
*
WX1BG
NOMESCO Finland
Total body MRI with high intensity magnet
71.8
6.5
7
*
L01XE26
ATC
[U] cabozantinib
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
WX1CG
NOMESCO Finland
Extensive total body MRI with high intensity magnet
+∞
6.3
6
*
361
Kela drug reimbursment
Axitinib
+∞
6.3
6
*
3012
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
6.3
6
*
1502
Kela drug reimbursment
Cabozantinib
+∞
6.3
6
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
M05BA02
ATC
clodronic acid; systemic
+∞
6.3
6
*
343
Kela drug reimbursment
Pazopanib
+∞
6.3
6
*
N18.0
ICD-10 Finland
End-stage renal disease
27.5
6.3
8
*
137
Kela drug reimbursment
Uraemia requiring dialysis
13.0
6.1
10
8
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
13.0
6.1
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
67
276
3.05
12.09
13.2
6.6
1.19
1.10
mmol/l
1.12
67
252
32
85
4.24
11.22
1.6
1.5
3.16
2.60
ug/l
0.36
25
66
18
31
6.23
7.09
3.8
1.9
29.23
14.04
iu/l
0.67
11
22
101
630
2.12
6.80
6.2
3.8
—
—
—
0
0
111
719
2.10
6.75
9.5
4.7
34.31
35.21
g/l
1.14
106
671
12
13
9.69
6.37
6.1
1.5
29.22
14.12
ug/l
1.00
12
13
69
396
2.08
5.60
4.1
2.1
—
—
—
0
0
81
517
1.90
4.74
5.7
3.7
0.11
0.39
e6/l
3.36
74
378
49
263
2.11
4.67
10.7
5.0
0.56
1.66
mmol/l
1.74
39
215
103
716
1.82
4.56
4.2
2.5
—
—
estimate
—
0
0
48
262
2.06
4.36
10.9
5.1
5.60
5.74
kpa
0.48
48
255
29
128
2.46
4.35
1.5
1.7
—
—
—
0
0
15
47
3.35
4.14
1.5
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
58
3.09
4.11
2.7
3.0
0.30
0.36
iu/ml
—
7
34
9
16
5.81
3.70
1.1
1.2
—
—
—
0
0
9
16
5.81
3.70
1.1
1.2
—
—
—
0
0
9
16
5.81
3.70
1.1
1.2
—
—
—
0
0
15
52
3.02
3.54
6.5
3.6
2.71
2.32
index
—
7
31
36
197
1.99
3.22
6.6
6.3
5.29
5.07
kpa
0.73
36
191
23
105
2.33
3.22
6.8
2.8
23.17
25.00
mmol/l
2.43
23
100
53
331
1.79
3.18
2.2
1.8
—
—
—
0
0
11
30
3.80
3.13
1.5
1.2
—
—
—
0
0
33
178
2.00
3.07
6.5
6.6
2.00
1.70
mmol/l
0.19
22
121
16
63
2.66
3.03
1.1
1.5
—
—
—
0
0
49
305
1.78
2.96
2.4
2.0
29.04
29.28
s
0.12
49
293
6
9
6.81
2.88
4.3
1.6
199.17
64.33
ng/l
—
6
9
6
9
6.81
2.88
6.7
4.2
—
—
—
0
0
40
236
1.85
2.87
2.0
1.9
—
—
—
0
0
9
23
4.03
2.80
7.4
5.1
10.73
11.78
mg/l
—
9
23
118
931
1.58
2.80
20.0
5.8
4.09
4.46
e9/l
0.97
109
779
127
1505
0.63
2.78
4.3
5.2
5.89
6.08
mmol/l
0.97
120
1350
17
73
2.44
2.73
2.2
1.7
3.05
2.33
ug/l
0.16
17
60
6
10
6.13
2.71
6.7
3.6
14.83
13.00
%
—
6
10
6
10
6.13
2.71
1.2
1.2
—
—
—
0
0
6
10
6.13
2.71
1.2
1.2
—
—
—
0
0
6
10
6.13
2.71
1.2
1.2
—
—
—
0
0
6
10
6.13
2.71
1.2
1.2
—
—
—
0
0
8
19
4.33
2.70
6.6
1.4
11.31
198.55
u/ml
—
8
19
149
1695
0.63
2.58
49.2
20.4
127.51
81.61
umol/l
4.69
144
1665
126
1486
0.64
2.58
8.1
5.0
2.06
2.01
mu/l
0.15
121
1335
30
168
1.91
2.52
11.7
6.2
23.33
23.95
mmol/l
0.83
30
168
8
21
3.91
2.49
1.6
1.2
—
—
—
0
0
37
223
1.79
2.48
9.8
5.2
5.59
4.64
kpa
1.07
37
215
12
46
2.70
2.40
1.9
2.9
101.17
90.07
%
0.93
12
46
40
251
1.73
2.34
2.0
1.8
—
—
—
0
0
12
47
2.64
2.31
1.5
1.4
—
—
—
0
0
6
13
4.71
2.28
1.3
1.3
—
—
—
0
0
26
145
1.90
2.22
4.7
1.8
64.73
66.26
g/l
0.39
26
128
147
1661
0.65
2.22
23.4
10.0
33.57
25.05
u/l
0.50
141
1595
8
24
3.42
2.20
1.6
1.3
—
—
—
0
0
129
1489
0.68
2.08
5.2
5.2
4.40
4.35
mmol/l
0.24
124
1377
54
384
1.54
1.92
5.6
4.3
147.06
411.30
ng/l
1.05
48
317
8
28
2.93
1.88
1.4
1.3
—
—
—
0
0
8
28
2.93
1.88
4.8
8.9
—
797.83
—
0
6
22
125
1.84
1.80
4.7
2.2
54.30
58.82
ml/min/173m2
—
10
50
146
1628
0.69
1.74
37.9
15.7
27.86
25.38
mg/l
0.46
135
1311
149
1654
0.69
1.71
45.0
19.8
139.06
139.66
mmol/l
2.06
143
1613
149
1654
0.69
1.71
45.6
19.9
4.17
4.02
mmol/l
7.49
143
1611
130
1471
0.72
1.61
6.9
7.3
40.87
40.41
mmol/mol
0.15
125
1365
7
26
2.75
1.59
1.3
1.3
—
—
—
0
0
10
44
2.33
1.58
1.6
1.3
—
—
—
0
0
10
44
2.33
1.58
1.6
1.3
—
—
—
0
0
11
53
2.13
1.41
1.0
1.2
—
—
—
0
0
9
42
2.19
1.35
1.7
1.3
—
—
—
0
0
33
229
1.52
1.32
6.6
6.3
-0.12
1.05
mmol/l
0.67
24
189
27
181
1.56
1.26
3.1
2.0
370.41
372.77
nmol/l
0.02
27
161
5
19
2.67
1.22
11.2
2.1
0.40
0.79
index
—
5
19
33
234
1.48
1.20
6.7
6.2
13.28
11.40
kpa
0.61
33
226
33
234
1.48
1.20
6.7
6.2
4.84
5.07
kpa
0.84
33
226
14
79
1.82
1.20
4.9
3.2
4.14
4.62
pmol/l
0.87
14
70
0
34
0.00
1.17
0.0
1.6
—
52.50
—
0
34
8
39
2.09
1.16
1.3
1.3
—
—
—
0
0
36
262
1.45
1.15
11.1
6.6
105.94
104.77
mmol/l
0.73
36
262
120
1055
1.30
1.14
8.2
5.1
6.86
6.77
mmol/l
0.17
115
1000
6
124
0.47
1.08
1.0
1.4
—
—
—
0
0
21
138
1.58
1.07
7.5
4.6
114.48
128.87
g/l
2.33
21
133
70
835
0.76
1.07
2.1
2.1
97.16
94.41
pmol/l
0.24
44
428
45
346
1.38
1.07
2.0
1.8
0.98
1.34
mg/l
1.06
37
276
29
396
0.69
1.05
3.0
2.8
0.72
0.76
ug/l
0.15
22
279
14
83
1.73
1.04
1.0
1.2
4.14
4.14
g/l
0.01
14
72
14
83
1.73
1.04
1.0
1.2
3.52
3.52
g/l
0.00
14
72
14
83
1.73
1.04
1.0
1.2
8.30
7.52
g/l
0.91
14
72
43
331
1.37
1.02
4.3
3.4
1.01
1.01
e6/l
0.00
31
178
10
54
1.89
0.98
1.0
1.2
—
—
—
0
0
0
30
0.00
0.98
0.0
1.1
—
34.50
—
0
8
13
78
1.71
0.94
2.8
1.5
—
—
—
0
0
17
110
1.59
0.93
7.6
4.7
0.52
0.56
%
0.23
17
110
10
57
1.79
0.85
2.8
4.0
—
—
—
0
0
6
31
1.96
0.85
1.2
1.2
—
—
—
0
0
20
279
0.69
0.82
1.8
1.9
—
—
—
0
0
47
573
0.77
0.82
4.9
3.9
20.18
25.36
%
2.36
25
289
17
115
1.52
0.79
7.6
4.6
1.26
1.08
%
0.58
17
115
6
34
1.79
0.77
1.0
1.2
—
—
—
0
0
12
75
1.63
0.76
2.8
1.4
—
—
—
0
0
11
69
1.63
0.70
1.0
1.2
10.50
10.00
g/l
0.16
11
58
17
236
0.70
0.69
1.5
1.3
26.90
12.73
u/ml
—
9
82
5
27
1.87
0.69
19.2
5.5
10.44
11.68
pmol/l
—
5
27
12
78
1.57
0.67
1.0
1.3
3.55
2.91
g/l
0.79
12
67
7
44
1.61
0.65
1.1
1.2
—
—
—
0
0
49
410
1.25
0.65
6.8
4.1
1.02
1.02
kg/l
0.77
39
270
12
79
1.55
0.64
1.1
1.4
—
—
—
0
0
5
30
1.68
0.62
2.8
2.1
1.23
1.19
mmol/l
—
5
30
5
30
1.68
0.62
2.8
2.1
109.20
106.07
mmol/l
—
5
30
40
479
0.80
0.60
9.6
4.0
0.00
0.00
estimate
—
10
147
64
727
0.83
0.58
5.9
4.3
788.59
93.96
ng/l
0.46
56
556
6
39
1.55
0.53
1.0
1.3
—
—
—
0
0
33
393
0.81
0.48
1.3
1.4
0.71
2.02
u/ml
—
7
95
7
47
1.51
0.48
1.3
1.2
—
—
—
0
0
17
129
1.34
0.47
7.6
7.6
24.79
24.56
mmol/l
0.16
17
123
38
324
1.21
0.44
4.6
3.6
0.97
1.91
e6/l
0.89
26
170
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
10
71
1.43
0.40
1.1
2.4
—
—
—
0
0
5
36
1.40
0.38
1.0
1.2
1.02
0.93
g/l
—
5
36
88
946
0.88
0.36
3.7
3.0
—
—
—
0
0
11
82
1.36
0.35
1.5
2.6
—
—
—
0
0
6
44
1.37
0.34
2.0
1.3
—
—
—
0
0
22
261
0.83
0.32
1.2
1.3
19.80
34.38
iu/ml
—
7
82
8
62
1.30
0.28
1.3
1.5
—
—
—
0
0
8
62
1.30
0.28
1.1
2.2
33.84
41.37
u/l
—
8
52
12
150
0.79
0.28
2.3
2.3
—
—
—
0
0
71
661
1.11
0.27
7.3
3.9
1.92
0.02
estimate
0.46
13
126
11
138
0.79
0.26
2.1
2.1
—
—
—
0
0
15
125
1.21
0.23
1.3
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
104.25
—
0
12
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.17
0.21
1.6
1.7
55.86
54.13
ug/l
—
5
35
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
6
51
1.18
0.19
1.5
2.5
332.50
77.41
ug/min
—
6
35
13
109
1.20
0.19
4.8
3.1
1.02
1.02
ratio
0.83
13
101
6
53
1.14
0.19
1.0
1.2
0.00
0.00
g/l
—
6
48
50
466
1.09
0.18
6.0
3.5
0.13
0.00
estimate
—
8
119
95
911
1.08
0.18
7.0
4.1
0.00
0.03
estimate
0.50
15
154
12
101
1.20
0.17
1.2
1.1
—
—
—
0
0
68
646
1.08
0.16
4.1
3.7
3275.38
1907.01
ng/l
1.23
61
556
93
903
1.05
0.11
6.9
4.1
83.69
0.00
estimate
0.48
16
164
92
895
1.05
0.10
6.9
4.0
0.00
0.00
estimate
-0.00
14
160
6
57
1.05
0.08
8.5
2.1
121.50
128.76
g/l
—
6
42
6
58
1.04
0.08
1.0
1.3
0.00
0.00
g/l
—
6
48
6
58
1.04
0.08
1.0
1.2
0.00
0.00
g/l
—
6
51
7
66
1.06
0.08
1.0
1.2
1.80
0.17
g/l
—
7
57
14
152
0.92
0.06
1.4
1.5
—
—
—
0
0
123
1223
1.01
0.01
6.9
4.5
16.17
12.83
mm/h
1.23
117
1117
12
118
1.02
0.00
19.3
3.8
1.24
1.22
mmol/l
0.42
12
96
19
194
0.98
0.00
17.7
7.9
—
—
—
0
0
11
106
1.04
0.00
2.1
1.5
—
—
—
0
0
59
595
0.99
0.00
5.7
4.2
33.35
9.36
mg/mmol
1.97
47
386
16
155
1.03
0.00
2.9
3.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
8.94
—
0
5
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.1
—
773.22
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
91.80
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
0.49
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1554.83
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
66.17
—
0
9
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_WILMS_TUMOR_WIDE – Wilms' tumor, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).